Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivonescimab monotherapy in advanced/metastatic RCC
NCT06472895Phase 2Not yet recruiting
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Jul 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
01
Overview
A Phase 2 trial of ivonescimab in renal cell carcinoma (RCC), sponsored by Peking University Cancer Hospital & Institute. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
ivonescimab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT06472895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06472895.